Enhanced prognosis of acute myeloid leukaemia patients with dm CEBPA bZIP ‐inf mutations: Insights from a multicentre Chinese cohort study
British Journal of Haematology · 2026-11 · 209 (5) · 2136-2147
DOI: 10.1111/bjh.70786 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 21.08.2026. Verfasst von Guanghui Chang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: CCAAT-Enhancer-Binding Proteins, Leukemia, Myeloid, Acute, Mutation. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Beijing Research Ward Excellence Program, Key Program of the National Natural Science Foundation of China.
Abstract (Originalsprache)
The 2022 European LeukemiaNet (ELN) recommendation redefined favourable‐risk CCAAT/enhancer binding protein alpha ( CEBPA )‐mutated acute myeloid leukaemia (AML) by in‐frame C‐terminal basic leucine zipper domain (bZIP) mutations rather than double CEBPA mutations. We analysed 411 CEBPA ‐mutated AML patients from six Chinese centres, classified as single‐mutant CEBPA bZIP‐other (sm CEBPA bZIP‐other ; n = 38), sm CEBPA bZIP‐inf ( n = 39), double‐mutant CEBPA other (dm CEBPA other ; n = 37) and dm CEBPA bZIP‐inf ( n = 297). Dm CEBPA bZIP‐inf patients were younger, had more de novo AML and showed distinct co‐mutation profiles, with more GATA binding protein 2 ( GATA2 ) and fewer nucleophosmin 1 ( NPM1 )/DNA methyltransferase 3 alpha ( DNMT3A ) mutations. Additionally, dm CEBPA bZIP‐inf patients had a higher composite complete remission (CRc) rate (94.6% vs. 84.2%–89.2%, p = 0.025) and better survival than the other three groups (3‐year overall survival [OS]: 80.0% vs. 57.4%–70.6%, p < 0.001; 3‐year disease‐free survival [DFS]: 74.5% vs. 45.4%–67.9%, p = 0.002). Multivariable Cox regression analysis showed that dm CEBPA bZIP‐inf and sm CEBPA bZIP‐inf had comparable survival, whereas dm CEBPA bZIP‐inf had better survival than sm CEBPA bZIP‐other and dm CEBPA other . However, among intensively treated patients, dm CEBPA bZIP‐inf was associated with superior survival compared with sm CEBPA bZIP‐inf (OS, hazard ratio [HR] = 1.542, p = 0.017; DFS, HR = 1.618, p = 0.014) and other two CEBPA groups in multivariable models. Among dm CEBPA bZIP‐inf patients, intensive chemotherapy (HR = 0.51, p = 0.012), adverse karyotype (HR = 1.52, p = 0.037), age ≥50 years (HR = 1.74, p = 0.044), neuroblastoma RAS viral oncogene homolog ( NRAS ) (HR = 1.64, p = 0.014) and colony‐stimulating factor 3 receptor ( CSF3R ) mutation (HR = 1.78, p = 0.049) were independent factors for OS. No significant difference in survival was observed between patients with CEBPA bZIP‐indel and CEBP bZIP‐ms mutations. In conclusion, the dm CEBPA bZIP‐inf subgroup displayed unique co‐mutation gene spectra and had better prognoses among the intensive treated cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- State Key Laboratory of Experimental Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
- Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, China.
- Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
ORCID-Profile: Pengcheng Shi, Liping Dou, Qian Jiang, Lanping Xu, Xiaojun Huang, Suning Chen, Feifei Tang
Förderung
- Beijing Research Ward Excellence Program
- Key Program of the National Natural Science Foundation of China
Zitieren
APA
Chang, G., Shi, P., Dou, L., Ren, J., Zhang, H., Jiang, Q., Jiang, H., Xu, L., Zhang, X., Huang, X., Chen, S., & Tang, F. (2026). Enhanced prognosis of acute myeloid leukaemia patients with dm CEBPA bZIP ‐inf mutations: Insights from a multicentre Chinese cohort study. British Journal of Haematology, 209(5), 2136-2147. https://doi.org/10.1111/bjh.70786
Vancouver
Chang G, Shi P, Dou L, Ren J, Zhang H, Jiang Q, et al. Enhanced prognosis of acute myeloid leukaemia patients with dm CEBPA bZIP ‐inf mutations: Insights from a multicentre Chinese cohort study. British Journal of Haematology. 2026;209(5):2136-2147. doi:10.1111/bjh.70786
BibTeX
@article{Chang2026,
author = {Chang, Guanghui and Shi, Pengcheng and Dou, Liping and Ren, Jinhai and Zhang, Hongyu and Jiang, Qian and Jiang, Hao and Xu, Lanping and Zhang, Xiaohui and Huang, Xiaojun and Chen, Suning and Tang, Feifei},
title = {Enhanced prognosis of acute myeloid leukaemia patients with dm CEBPA bZIP ‐inf mutations: Insights from a multicentre Chinese cohort study},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {5},
pages = {2136--2147},
doi = {10.1111/bjh.70786}
}
EUVIMED